Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Axon Therapies just landed $32mn and a new CEO—can an implant-free heart failure therapy really change the game? Find out how Axon Therapies’ $32M Series A and new CEO could speed implant-free heart failure trials and European expansion—see what it means for patients. bySoujanya RaviSeptember 25, 2025